相关实验视频
Updated: Jun 28, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.6K
血小板膜涂层的r-SAK通过向血栓来提高血栓溶解效率
Rui Hua1, Mingxi Li2, Qingxia Lin1
1Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
ACS applied materials & interfaces
|April 16, 2024
概括
血小板膜覆盖的复合性稳定酶 (PM-r-SAK) 增强了对血栓性疾病的血栓治疗. 这种新的方法提高了疗效,减少了再通道化时间,在治疗阻塞血管方面提供了有前途的进步.
科学领域:
- 生物医学工程 生物医学工程
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓溶解药物治疗对于血栓性疾病至关重要,但在有效性和出血风险方面面临限制.
- 再组合稳酶 (r-SAK) 是一种有效的第三代血栓解毒剂.
- 血小板膜涂层正在探索,以提高药物输送和疗效.
研究的目的:
- 开发和评估一个经血小板膜 (PM) 涂层的复合性稳定酶 (PM-r-SAK),以改善血栓解压疗法.
- 与标准r-SAK相比,评估PM-r-SAK的血栓解毒疗效和再通道化特性.
主要方法:
- 通过覆盖复合稳定基酶与血小板膜来开发PM-r-SAK.
- 使用子大腿动脉血栓形成模型进行体内研究,以评估再通道化时间和再输液.
- 在试验室中使用抗血小板药物 (阿司匹林,蒂卡格勒勒) 患者的血小板贫乏血进行血小板溶解实验.
主要成果:
- 与r-SAK的4倍高剂量相比,PM-r-SAK表现出同等或更高的血栓抑制疗效.
- 在封闭的子大腿动脉模型中,PM-r-SAK显著减少了初始再通道化时间.
- 服用阿司匹林和提卡格勒勒的患者的血抑制了PM-r-SAK的血栓溶解疗效,这表明有针对性的活性.
结论:
- 血小板膜涂层显著增强了复合性稳定酶的血栓解毒功效.
- PM-r-SAK表现出改善的血栓向活性和减少的再通道化时间.
- 研究结果表明,PM-r-SAK是一种有前途的治疗策略,用于血栓性疾病.
相关概念视频
01:22Formation of the Platelet Plug
6.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:16Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
01:18Structure and Function of Platelets
1.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.1K